Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment: Results of a Delphi survey

Andrianos Tsekrekos, Sönke Detlefsen, Robert Riddell, James Conner, Luca Mastracci, Kieran Sheahan, Jayant Shetye, Lars Lundell, Michael Vieth

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

52 Downloads (Pure)

Resumé

Studies investigating the histopathologic response of gastric carcinoma to neoadjuvant treatment have used a variety of different tumor regression grading systems. The aim of this Delphi survey was to review the available systems and reach consensus on a potential international standard. An international e-mail–based Delphi survey involving 6 expert pathologists was undertaken between January and October 2017. A questionnaire consisting of 72 items was formed after reviewing the 5 available systems. Rating of the items was done on a symmetric 4-point Likert-type scale, and feedback was provided between rounds. A total of 4 rounds were required to reach consensus on 97% of the items covering the topics: (1) specimen processing, (2) gross examination, (3) cross sectioning/method of sampling, (4) staining, (5) immunohistochemistry, (6) assessment of tumor regression in response to neoadjuvant therapy, (7) tumor regression grading, (8) assessment of regression of nodal metastases, and (9) role of histologic tumor type. Through the outcome of this comprehensive Delphi study, a group of experts is proposing a 4-tiered system for the grading of regression of the primary tumor, combined with a 3-tiered system for lymph node metastases. Grade 1 represents complete response, grade 2 contains less than 10% residual tumor (subtotal regression), grade 3 contains 10% to 50% residual tumor (partial regression), and grade 4 contains greater than 50% residual tumor (minimal/no regression). The addition of “a” “b” or “c” indicates complete, partial, or no response of lymph node metastases. It is recommended to use this grading system irrespective of histologic subtype.

OriginalsprogEngelsk
TidsskriftHuman Pathology
Vol/bind84
Sider (fra-til)26-34
ISSN0046-8177
DOI
StatusUdgivet - feb. 2019

Fingeraftryk

Neoadjuvant Therapy
Neoplasm Grading
Residual Neoplasm
Lymph Nodes
Delphi Technique
Neoplasms
Surveys and Questionnaires

Bibliografisk note

Copyright © 2018 Elsevier Inc. All rights reserved.

Citer dette

Tsekrekos, Andrianos ; Detlefsen, Sönke ; Riddell, Robert ; Conner, James ; Mastracci, Luca ; Sheahan, Kieran ; Shetye, Jayant ; Lundell, Lars ; Vieth, Michael. / Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment : Results of a Delphi survey. I: Human Pathology. 2019 ; Bind 84. s. 26-34.
@article{fc8c0ee72a3e486fbd04bdd76217856c,
title = "Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment: Results of a Delphi survey",
abstract = "Studies investigating the histopathologic response of gastric carcinoma to neoadjuvant treatment have used a variety of different tumor regression grading systems. The aim of this Delphi survey was to review the available systems and reach consensus on a potential international standard. An international e-mail–based Delphi survey involving 6 expert pathologists was undertaken between January and October 2017. A questionnaire consisting of 72 items was formed after reviewing the 5 available systems. Rating of the items was done on a symmetric 4-point Likert-type scale, and feedback was provided between rounds. A total of 4 rounds were required to reach consensus on 97{\%} of the items covering the topics: (1) specimen processing, (2) gross examination, (3) cross sectioning/method of sampling, (4) staining, (5) immunohistochemistry, (6) assessment of tumor regression in response to neoadjuvant therapy, (7) tumor regression grading, (8) assessment of regression of nodal metastases, and (9) role of histologic tumor type. Through the outcome of this comprehensive Delphi study, a group of experts is proposing a 4-tiered system for the grading of regression of the primary tumor, combined with a 3-tiered system for lymph node metastases. Grade 1 represents complete response, grade 2 contains less than 10{\%} residual tumor (subtotal regression), grade 3 contains 10{\%} to 50{\%} residual tumor (partial regression), and grade 4 contains greater than 50{\%} residual tumor (minimal/no regression). The addition of “a” “b” or “c” indicates complete, partial, or no response of lymph node metastases. It is recommended to use this grading system irrespective of histologic subtype.",
keywords = "Consensus, Delphi, Gastric cancer, Histopathologic tumor regression grade, Neoadjuvant treatment",
author = "Andrianos Tsekrekos and S{\"o}nke Detlefsen and Robert Riddell and James Conner and Luca Mastracci and Kieran Sheahan and Jayant Shetye and Lars Lundell and Michael Vieth",
note = "Copyright {\circledC} 2018 Elsevier Inc. All rights reserved.",
year = "2019",
month = "2",
doi = "10.1016/j.humpath.2018.08.028",
language = "English",
volume = "84",
pages = "26--34",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B.Saunders Co.",

}

Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment : Results of a Delphi survey. / Tsekrekos, Andrianos; Detlefsen, Sönke; Riddell, Robert; Conner, James; Mastracci, Luca; Sheahan, Kieran; Shetye, Jayant; Lundell, Lars; Vieth, Michael.

I: Human Pathology, Bind 84, 02.2019, s. 26-34.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment

T2 - Results of a Delphi survey

AU - Tsekrekos, Andrianos

AU - Detlefsen, Sönke

AU - Riddell, Robert

AU - Conner, James

AU - Mastracci, Luca

AU - Sheahan, Kieran

AU - Shetye, Jayant

AU - Lundell, Lars

AU - Vieth, Michael

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2019/2

Y1 - 2019/2

N2 - Studies investigating the histopathologic response of gastric carcinoma to neoadjuvant treatment have used a variety of different tumor regression grading systems. The aim of this Delphi survey was to review the available systems and reach consensus on a potential international standard. An international e-mail–based Delphi survey involving 6 expert pathologists was undertaken between January and October 2017. A questionnaire consisting of 72 items was formed after reviewing the 5 available systems. Rating of the items was done on a symmetric 4-point Likert-type scale, and feedback was provided between rounds. A total of 4 rounds were required to reach consensus on 97% of the items covering the topics: (1) specimen processing, (2) gross examination, (3) cross sectioning/method of sampling, (4) staining, (5) immunohistochemistry, (6) assessment of tumor regression in response to neoadjuvant therapy, (7) tumor regression grading, (8) assessment of regression of nodal metastases, and (9) role of histologic tumor type. Through the outcome of this comprehensive Delphi study, a group of experts is proposing a 4-tiered system for the grading of regression of the primary tumor, combined with a 3-tiered system for lymph node metastases. Grade 1 represents complete response, grade 2 contains less than 10% residual tumor (subtotal regression), grade 3 contains 10% to 50% residual tumor (partial regression), and grade 4 contains greater than 50% residual tumor (minimal/no regression). The addition of “a” “b” or “c” indicates complete, partial, or no response of lymph node metastases. It is recommended to use this grading system irrespective of histologic subtype.

AB - Studies investigating the histopathologic response of gastric carcinoma to neoadjuvant treatment have used a variety of different tumor regression grading systems. The aim of this Delphi survey was to review the available systems and reach consensus on a potential international standard. An international e-mail–based Delphi survey involving 6 expert pathologists was undertaken between January and October 2017. A questionnaire consisting of 72 items was formed after reviewing the 5 available systems. Rating of the items was done on a symmetric 4-point Likert-type scale, and feedback was provided between rounds. A total of 4 rounds were required to reach consensus on 97% of the items covering the topics: (1) specimen processing, (2) gross examination, (3) cross sectioning/method of sampling, (4) staining, (5) immunohistochemistry, (6) assessment of tumor regression in response to neoadjuvant therapy, (7) tumor regression grading, (8) assessment of regression of nodal metastases, and (9) role of histologic tumor type. Through the outcome of this comprehensive Delphi study, a group of experts is proposing a 4-tiered system for the grading of regression of the primary tumor, combined with a 3-tiered system for lymph node metastases. Grade 1 represents complete response, grade 2 contains less than 10% residual tumor (subtotal regression), grade 3 contains 10% to 50% residual tumor (partial regression), and grade 4 contains greater than 50% residual tumor (minimal/no regression). The addition of “a” “b” or “c” indicates complete, partial, or no response of lymph node metastases. It is recommended to use this grading system irrespective of histologic subtype.

KW - Consensus

KW - Delphi

KW - Gastric cancer

KW - Histopathologic tumor regression grade

KW - Neoadjuvant treatment

U2 - 10.1016/j.humpath.2018.08.028

DO - 10.1016/j.humpath.2018.08.028

M3 - Journal article

C2 - 30217622

VL - 84

SP - 26

EP - 34

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -